{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:57Z","timestamp":1761512937103},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/s1040-8428(11)70006-3","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T09:20:20Z","timestamp":1298539220000},"page":"S31-S37","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S1","title":["Anticancer evidence for zoledronic acid across the cancer continuum"],"prefix":"10.1016","volume":"77","author":[{"given":"Luis","family":"Costa","sequence":"first","affiliation":[]},{"given":"Peter","family":"Harper","sequence":"additional","affiliation":[]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1040-8428(11)70006-3_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/S1040-8428(11)70006-3_bib3","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/S1040-8428(11)70006-3_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/S1040-8428(11)70006-3_bib5","series-title":"Zometa (zoledronic acid) injection [package insert]","year":"2008"},{"key":"10.1016\/S1040-8428(11)70006-3_bib6","series-title":"Bonefos (disodium clodronate) [package insert]","year":"2008"},{"key":"10.1016\/S1040-8428(11)70006-3_bib7","series-title":"Aredia (pamidronate disodium) injection [package insert]","year":"2008"},{"key":"10.1016\/S1040-8428(11)70006-3_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/S1040-8428(11)70006-3_bib9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1040-8428(11)70006-3_bib11","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Poster presented at American Society of Clinical Oncology Breast Cancer Symposium, 2009 [abstract 213]."},{"issue":"Suppl","key":"10.1016\/S1040-8428(11)70006-3_bib12","first-page":"9s","article-title":"Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809","volume":"26","author":"Shapiro","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new m\u00e9tastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S1040-8428(11)70006-3_bib14","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/S1040-8428(11)70006-3_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib16","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib17","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/S1040-8428(11)70006-3_bib18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"10.1016\/S1040-8428(11)70006-3_bib19","first-page":"20s","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib20","doi-asserted-by":"crossref","unstructured":"Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at 31st Annual San Antonio Breast Cancer Symposium, 2008 [abstract 2048].","DOI":"10.1158\/0008-5472.SABCS-2048"},{"key":"10.1016\/S1040-8428(11)70006-3_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib22","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/S1040-8428(11)70006-3_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib24","doi-asserted-by":"crossref","unstructured":"Coleman R, Bundred N, de Boer R, Llombart A, Campbell I, Neven P, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at 32nd Annual San Antonio Breast Cancer Symposium, 2009 [abstract 4082].","DOI":"10.1158\/0008-5472.SABCS-09-4082"},{"key":"10.1016\/S1040-8428(11)70006-3_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/S1040-8428(11)70006-3_bib26","first-page":"74s","article-title":"Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer","volume":"28","author":"Gnant","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib27","doi-asserted-by":"crossref","unstructured":"Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Adjuvant treatment with zoledronic acid in stage II\/III breast cancer. The AZURE trial (BIG 01\/04). Presented at 33rd Annual San Antonio Breast Cancer Symposium, 2010 [abstract S4-5].","DOI":"10.1158\/0008-5472.SABCS10-S4-5"},{"key":"10.1016\/S1040-8428(11)70006-3_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone m\u00e9tastases in patients with recurrent solid tumors that did not present with bone m\u00e9tastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Med Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib30","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/S1040-8428(11)70006-3_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Aviles","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib32","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/S1040-8428(11)70006-3_bib33","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2174\/156800909789760267","article-title":"Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials","volume":"9","author":"Gnant","year":"2009","journal-title":"Curr Cancer Drag Targets"},{"issue":"1","key":"10.1016\/S1040-8428(11)70006-3_bib34","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1040-8428(11)70003-8","article-title":"The backbone of progress - preclinical studies and innovations with zoledronic acid","volume":"77","author":"Green","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/S1040-8428(11)70006-3_bib36","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1040-8428(11)70006-3_bib37","doi-asserted-by":"crossref","unstructured":"Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkko-nen J, et al. Zoledronic acid-induced IPP\/ApppI (phosphoantigen) accumulation in human breast cancer cells correlates with V\u03b39V\u03b42 T cell-mediated cancer cell death in vitro and in vivo. Presented at International Bone and Mineral Society Meeting, 2010 [abstract 93].","DOI":"10.1016\/j.bone.2010.01.096"},{"key":"10.1016\/S1040-8428(11)70006-3_bib38","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1016\/S1040-8428(11)70006-3_bib39","first-page":"748s","article-title":"Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment","volume":"28","author":"Normanno","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm0806-875","article-title":"Is cancer a disease of self-seeding?","volume":"12","author":"Norton","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/S1040-8428(11)70006-3_bib41","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/S1462399408000616","article-title":"Molecular mechanisms and treatment of bone metastasis","volume":"10","author":"Clines","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/S1040-8428(11)70006-3_bib42","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1040-8428(11)70006-3_bib43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2008.48","article-title":"The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites","volume":"22","author":"Shiozawa","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/S1040-8428(11)70006-3_bib44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"1","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1016\/S1040-8428(11)70006-3_bib45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/S1040-8428(11)70006-3_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone m\u00e9tastases from solid tumors and elevated bone r\u00e9sorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/S1040-8428(11)70006-3_bib47","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone m\u00e9tastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/S1040-8428(11)70006-3_bib48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib49","unstructured":"Body J-J, Cook R, Costa L, Brown J, Terpos E, Saad F, et al. Possible survival benefits from zoledronic acid treatment in patients with bone m\u00e9tastases from solid tumors and poor prognostic features. Presented at XI International Meeting on Cancer Induced Bone Disease, 2009 [abstract 71]."},{"key":"10.1016\/S1040-8428(11)70006-3_bib50","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/S1040-8428(11)70006-3_bib51","first-page":"S99","article-title":"Use of zoledronic acid in lung cancer","volume":"5","author":"Calderone","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4161\/cbt.10.6.12611","article-title":"Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial","volume":"10","author":"Facchini","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/S1040-8428(11)70006-3_bib53","doi-asserted-by":"crossref","unstructured":"Frassoldati A, Brufsky A, Bundred N, Lambert-Falls R, Hadji P, Schenk N, et al. Effect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: a 24-month integrated follow-up of the Z-FAST\/ZO-FAST trials. Presented at Primary Therapy of Early Breast Cancer 11th International Conference, 2009 [abstract 132].","DOI":"10.1016\/S0960-9776(09)70164-X"},{"issue":"Suppl 1","key":"10.1016\/S1040-8428(11)70006-3_bib54","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1053\/j.seminoncol.2010.06.008","article-title":"Potential anticancer properties of bisphosphonates","volume":"37","author":"Neville-Webbe","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib55","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human \u03b3\u03b4T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/S1040-8428(11)70006-3_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2008.07.008","article-title":"Are bisphosphonates the suitable anticancer drags for the elderly?","volume":"69","author":"Santini","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/S1040-8428(11)70006-3_bib57","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1464-410X.2005.05740.x","article-title":"Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone m\u00e9tastases secondary to genitourinary cancers","volume":"96","author":"Saad","year":"2005","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/S1040-8428(11)70006-3_bib58","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1040-8428(11)70005-1","article-title":"Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?","volume":"77","author":"Morgan","year":"2011","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811700063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811700063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T16:19:26Z","timestamp":1560010766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842811700063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":58,"alternative-id":["S1040842811700063"],"URL":"https:\/\/doi.org\/10.1016\/s1040-8428(11)70006-3","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}